Loading
An alpha-emitting radioligand met all its primary endpoints, with responses in more than half of patients new to radioligand therapy.
ALPHAMEDIX-02, trial NCT05153772 sponsored by RadioMedix, Orano Med and Sanofi and reported in 2025, showed that the alpha-emitting radioligand 212Pb-DOTAMTATE met all its primary endpoints, with responses in more than half of patients with somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumours who were new to radioligand therapy. In the single-arm phase 2 the objective response rate in PRRT-naive patients was 54.3 percent, most were still progression-free around three years, and the PRRT-exposed cohort was largely progression-free at eighteen months, as Sanofi reported in October 2025; the drug holds Breakthrough Therapy designation and the registrational path is being finalised. OnCo links it to targeted alpha therapy, PRRT, 212Pb-DOTAMTATE and the pairing of beta then alpha PRRT. Whether a randomised trial confirms superiority over lutetium is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Beta PRRT → alpha PRRT, Targeted alpha therapy, Neuroendocrine tumours.
Shares RadioMedix, Neuroendocrine tumours.
Shares SSTR antagonist radioligands to increase tumour dose, Peptide receptor radionuclide therapy (PRRT), Neuroendocrine tumours.
Shares Orano Med, Targeted alpha therapy.
Shares Orano Med, Neuroendocrine tumours.
Shares SSTR antagonist radioligands to increase tumour dose, Peptide receptor radionuclide therapy (PRRT), Neuroendocrine tumours.
Shares Peptide receptor radionuclide therapy (PRRT), Targeted alpha therapy, Neuroendocrine tumours.
Shares Orano Med, Targeted alpha therapy.